Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.50 |
| ▸ | SCTR | P47872 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616372 | 0.92 | GLP1R (0.56) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL2465543 | 0.92 | GLP1R (0.50) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL6117711 | 0.90 | GLP1R (0.62) | GLP1RSCTR | |
| SCHEMBL3120134 | 0.90 | GLP1R (0.62) | GLP1RSCTR | |
| SCHEMBL29394888 | 0.89 | GLP1R (0.58) | GLP1RSCTR | |
| SCHEMBL29860251 | 0.88 | OPRM1 (0.61) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL29860168 | 0.88 | OPRM1 (0.57) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL31243563 | 0.87 | GLP1R (0.60) | GLP1R | |
| SCHEMBL677433 | 0.87 | GLP1R (0.43) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL31741239 | 0.86 | GLP1R (0.55) | GLP1RSCTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | GLP1R 46/4885SCTR 1105/4885OPRM1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.